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Methods
Patients
The design and results of the FAME 1 and FAME 2 studies have been reported previously. [5] [6] [7] 9 Both are international, multicenter, prospective, randomized clinical trials with comparable inclusion and exclusion criteria. In brief, the FAME 1 trial enrolled patients with angiographic multivessel coronary artery disease amenable for PCI. Patients were randomized either to an FFR-guided or to an angiography-guided approach. In the FFR-guided arm, only lesions with an FFR ≤0.80 were treated by PCI, whereas in the angiography-guided arm, all narrowings with ≥50% diameter stenosis (DS) were treated by PCI. Stenting was performed using first-generation DES. The primary end point was the composite of all-cause death, nonfatal myocardial infarction (MI), and any repeat revascularization (major adverse cardiac events [MACE] ) at 1 year as adjudicated by a clinical event committee. A prespecified secondary end point of the study was the MACE rate at 2 years. 17 The FAME 2 trial enrolled patients with stable angina, stabilized acute coronary syndrome or silent ischemia with 1, 2, or 3-vessel disease. Patients having at least one stenosis with an FFR ≤0.80 were randomized to FFR-guided PCI plus best available medical therapy or best available medical therapy alone. PCI was performed using secondgeneration DES. The primary end point of the study was a composite of all-cause death, nonfatal MI, and unplanned hospitalization leading to urgent revascularization at 2 years. A prespecified secondary end point of the study was any repeat revascularization at 2 years. 7 In both trials, patients were included only if there was at least one clearly identifiable focal narrowing at angiography deemed to be amenable for stenting. Patients with only diffuse disease were not considered for the study as it was supposed that no local treatment (stenting) might significantly improve vessel hemodynamics.
The present analysis includes all patients who had post-PCI FFR measurement from the FFR-guided arm of the FAME 1 trial and the PCI plus best available medical therapy arm of the FAME 2 trial. Obtaining post-PCI FFR was not mandated per protocol. Institutional research board has approved the present study. All patients gave informed consent before enrollment to FAME 1 or FAME 2 trials.
Vessels
The present study investigated the relationship between post-PCI FFR values and clinical outcome at vessel level. All angiographic characteristics and end points are reported at vessel level. Coronary stenosis severity was assessed by visual estimation and reported, according to the main trials, in the following strata of DS: <50%, 50% to 69%, 70% to 90%, and >90%.
End Points
Follow-up was censored 2 years after enrollment or at the time of death. The primary end point of the present analysis is the vesseloriented composite end point (VOCE) at 2 years, defined as the composite of vessel-related cardiovascular death, vessel-related spontaneous (ie, nonperiprocedural) MI, and ischemia-driven target vessel revascularization (TVR, both urgent and nonurgent). All events were adjudicated by an independent clinical event committee, blinded to randomization allocation. For the present analysis, all the original narratives were reviewed and evaluated independently by 2 interventional cardiologists (Z.P. and G.G.T.), blinded to baseline clinical and procedural characteristics, as well as to post-PCI FFR value. Events were designated as vessel-related or not vessel-related.
WHAT IS KNOWN
• Fractional flow reserve with a clear cutoff value of 0.80 is the current gold standard for invasive hemodynamic evaluation of coronary stenoses.
• True prognostic value of fractional flow reserve, measured right after percutaneous coronary intervention with drug-eluting stent is unknown.
WHAT THE STUDY ADDS
• Low post-percutaneous coronary intervention fractional flow reserve is associated with worse longterm clinical outcome on vessel level.
• However, after percutaneous coronary intervention, there is no well-defined fractional flow reserve cutoff value, which could be applied for individual clinical decisions or used as surrogate end point in future studies. In case of disagreement, the narrative was reviewed again until a joint agreement was met. Death was categorized as either cardiovascular or noncardiovascular. Any death of unknown cause was counted as cardiovascular. Cardiovascular death in patients with multiple index stenoses was assigned to each index stenosis. Any spontaneous MI without clearly identifiable culprit vessel was counted as target vessel related. Any spontaneous MI in patients with multiple index stenoses without clearly identifiable culprit vessel was assigned to each index stenosis.
Statistical Analysis
Continuous variables are presented as mean±SD or median and interquartile range from the 25th to the 75th percentile; categorical data are presented as numbers and percentages, as appropriate. Normal distribution was tested with D'Agostino K2 test. Comparisons between continuous variables were performed using Student t test or Mann-Whitney test, as appropriate. Comparisons between categorical variables were evaluated using Pearson χ 2 or Fisher exact test, as appropriate. The predictive value of clinical and angiographic parameters on post-PCI FFR was determined by deriving the β-coefficient in a generalized linear mixed-effects regression model after standardization to achieve that the variance of dependent and independent variable was 1. Sensitivity, specificity, and optimal diagnostic cutoff values were defined from the calculated receiver-operator characteristic curves, as appropriate. In lesion-level-based analysis, general procedural characteristics and generalized mixed-effects models were used with patient identification as random effect to account for the nonindependence of lesions within the same patient. The multilevel mixed-effects model used for lesion-level analyses fitted random intercepts to account for the correlation of characteristics of lesions within patients. In analysis of time-to-event outcomes, Cox regression was used with robust SE to account for the correlation between lesions. Proportional-hazards test based on Schoenfeld residuals was performed after fitting a crude and adjusted survival model. (Table  I in the Data Supplement) The added predictive ability of the new predictor (baseline FFR) over and above a reference model (post-PCI FFR) was assessed by integrated discrimination improvement index based on logistic model. 21 Kaplan-Meier curves were constructed for the primary end point of VOCE at 2-year follow-up. Two sided P values were reported throughout and P values smaller than 0.05 were considered as statistically significant. Analyses were performed with Prism 
Results
Patients and Vessels
Of the 509 patients randomized to the FFR-guided arm in the FAME 1 trial, 352 had post-PCI FFR measurement (69.2%). Of the 447 patients randomized to PCI plus medical therapy in the FAME 2 trial, 287 (64.2%) had post-PCI FFR measurement. Together, these 639 patients constitute the study group of the present analysis. The baseline characteristics of the patient group are summarized in Table 1 . Patients from the FAME 1 and FAME 2 trials were similar, except for the higher rate of hypertension and more imbalanced angina severity as defined by the Canadian Cardiovascular Society classification in the FAME 2 population.
In these 639 patients, 838 vessels were evaluated in the present analysis, of which 433 (51.7%) were left anterior descending (LAD), 217 (25.9%) were right coronary arteries, and 188 (22.4%) were circumflex arteries. The median value of baseline FFR measurements was 0.68 (0.54-0.74): 0.69 (0.58-0.75) in the LAD, 0.66 (0.50-0.74) in the circumflex arteries, and 0.64 (0.50-0.74) in the right coronary arteries. The median value of post-PCI FFR measurements was 0.90 (0.86-0.94). The distribution is indicated in Figure 1 . Detailed lesion and procedural characteristics are reported in Table 2 . No relationship was found between baseline FFR and post-PCI FFR values ( Figure I in the Data Supplement). Lesions were more frequently located in the LAD. However, serial stenoses occurred more often in the FAME 1 trial in which mean baseline FFR was also lower. Still, the mean post-PCI FFR value was similar between the 2 study populations.
By computing standardized coefficient in multiple regression analysis, male sex, diabetes mellitus, and LAD location were found as significant predictors of a lower post-PCI FFR value, whereas use of multiple stents in the given vessel showed a strong trend to predict lower post-PCI FFR value. Higher baseline DS and higher baseline FFR predict higher post-PCI FFR value (Table 3) . Comparison between extended (post-PCI FFR+baseline FFR) and reference (post-PCI FFR alone) models shows that there is a small difference between their predictive ability (integrated discrimination improvement=0.00565; z=2.53; P=0.012).
Clinical Follow-Up
Complete follow-up was obtained for 93.8% of the patients. The mean follow-up was 23.6±2.8 months (time to censored event between 0 and 24 months). Altogether, 69 events were detected in 58 treated vessels (6.9%). The distribution is indicated in Figure 2 When grouping the vessels in tertiles according to the post-PCI FFR value (<0.88 versus 0.88-0.92 versus >0.92; Table 4 ), a significant difference was found in the rate of VOCE with lowest incidence in the upper tertile (9.2% versus 7.9% versus 3.8%, respectively; P=0.029).
Comparing the 2-year outcome of lower and upper tertiles of post-PCI FFR, a significant difference was found favoring the upper tertile in terms of overall VOCE (9.2% versus 3.8%, respectively; hazard ratio [HR], 1.46; 95% CI, 1.02-2.08; P=0.037) and TVR (7.0% versus 2.4%, respectively; HR, Figure 3 ; Table 5 ).
When adjusted to sex, hypertension, diabetes mellitus, target vessel, serial stenosis, and baseline percentage DS, a strong trend was preserved in terms of TVR (HR, 1.55; 95% CI, 0.97-2.46; P=0.066) favoring the upper tertile compared with the lower, as shown in Table 5 .
Definition of a Potential Cutoff Value
Receiver-operator characteristic curve analysis was performed to identify a potential cutoff with prognostic value for VOCE during 2-year follow-up (Figure 4) 
Discussion
Summary of Findings
The present study analyzes the relationship between the post-PCI FFR value immediately after DES implantation and the vessel-related events. The main findings of the present analysis can be summarized as follows:
1. Vessels with a lower residual FFR after PCI with implantation of at least one DES had significantly more clinical events compared with vessels with higher post-PCI FFR values. The difference was preserved as a strong trend even after adjustment for various clinical, angiographic, and procedural characteristics. Therefore, these findings extend the overall prognostic value of FFR to post-PCI measurements. 2. Male sex, diabetes mellitus, LAD lesion location, and the use of multiple stents are associated with a lower Figure 3 . Two-year vessel-related event rates in lower, middle, and high post-percutaneous coronary intervention (PCI) fractional flow reserve (FFR) tertiles. In the unadjusted comparison of the 2-year outcome of the tertiles, grouped according to post-PCI FFR value, a significant difference was found in terms of overall vessel-oriented composite end point and target vessel revascularization, favoring the upper tertile. No statistically significant difference was observed in vessel-related spontaneous myocardial infarction and vessel-related cardiovascular death. CI indicates confidence interval; and HR, hazard ratio. Prognostic Value of Post-PCI FFR post-PCI FFR achieved after angiographically successful revascularization. 3. Nevertheless, the low likelihood ratio indicates that there is no discrete post-PCI FFR value that could be proposed to rule in or to rule out vessel-oriented adverse events. Accordingly, post-PCI FFR cannot be advocated as a clinical surrogate nor as a guide for PCI optimization.
Previous Data With Post-PCI FFR
The present findings derived from the largest population studied to date confirm previous observational registries, suggesting the prognostic value of post-PCI FFR. In the bare metal stent era, a large registry showed a clear relationship between the FFR, measured immediately after PCI, and the MACE rate at 6-month follow-up. 22 In the DES era, Doh et al on the ability of post-PCI FFR to predict TLR, long-term event-free survival, or restenosis. [25] [26] [27] [28] In contrast, the present analysis was based on 2 large-scale, multicentric randomized trials. Approximately two thirds of the total population that underwent FFR-guided DES placement in these trials had post-PCI FFR measurements. Consequently, the number of patients included in the present analysis is twice as large as most of the previously published studies from the DES era together. [23] [24] [25] [26] [27] The end point-VOCE-was used to match as closely as possible post-PCI vessel characteristics and patients clinical outcome. Moreover, all end points were adjudicated by an independent clinical event committee blinded to all clinical data including post-PCI FFR values.
Evaluation of Post-PCI Results
In the vast majority of PCI cases, final results are gauged by angiography. A residual stenosis of >20% has often been considered a suboptimal post-PCI result. [29] [30] [31] Many of the mechanisms of early and late post-PCI failure have been unraveled by intravascular ultrasound. However, intravascular ultrasound-based guidance of PCI did not consistently translate into improved clinical outcome 32, 33 and was, therefore, not adopted in clinical practice to evaluate the result of PCI. Optical coherence tomography further improved the visualization of morphological details. Even though post-PCI optical coherence tomography images often trigger additional maneuvers aiming at improving the immediate results, 34, 35 there is no convincing indication that a systematic use of optical coherence tomography improves clinical outcome. An imaging modality focuses on the stented segment, not taking into account the entire length of the artery nor the myocardial mass depending on the stented segment. In contrast, post-PCI FFR is a marker of the residual epicardial resistance of the entire artery during maximal microvascular vasodilation. Several mechanisms can concur to a post-PCI FFR value <1.0: the presence of a second lesion, residual diffuse disease, pressure sensor drift, and suboptimal stent deployment. 36 Accordingly, the different mechanisms might have different weight in determining clinical outcome. A pullback maneuver of the sensor under steadystate hyperemia is able to identify which one is prevailing. 37 In case of abnormal FFR related to a pressure gradient within the stented segment, additional intracoronary imaging is warranted to unravel the mechanism of this focal pressure drop. In the patients included in the FAME trials, a pressure pull back was not performed systematically and, when done, additional maneuvers to correct and improve FFR were not advocated. However, daily experience shows that after an angiographically successful PCI, the pressure gradient is often diffusely distributed over the length of the artery caused by diffuse atherosclerosis, which may or may not be visible by angiography. FFR values measured in the present study were obtained when the PCI was considered successful and should, therefore, be considered merely documentary.
Perspectives
Our findings raise the question whether optimization of post-PCI FFR with a more extensive intervention could improve clinical outcome. An answer to this question could only be derived from an appropriately sized trial. On the basis of the present findings, such a randomized trial comparing post-PCI FFR-based optimization with routine practice would require ≈4200 patients to detect a 30% relative risk reduction of VOCE at 2 years (from 7.9% in the control group receiving routine care to 3.6% in the experimental group with 80% power at a 2-sided α of 0.05). In the light of our results, such a trial currently seems hardly justifiable.
Limitations
It is important to stress that the post-PCI values were merely documentary because, after angiographically successful PCI, according to protocol, no additional maneuver was undertaken to achieve a higher FFR value. Second, patients and their treating physicians could be aware of the post-PCI FFR value. However, all patients had angiographically successful PCI, and the vast majority had a nonsignificant FFR on completion of the intervention (Figure 1) . Third, albeit measurement of post-PCI FFR was recommended in the trials, it was performed only in two thirds of all cases, suggesting some selection bias. It can indeed be speculated that post-PCI FFR measurements were preferentially performed in cases with a good angiographic result. Yet, this potential selection bias could actually only strengthen our findings. Fourth, we did not specifically investigate the effect of medical therapy and compliance of patients with the medical regimen; however, both trials mandated optimal medical therapy, and the FAME 2 trial reported on the medical therapy of different arms of the trial. 6, 7 Finally, because post-PCI pullback recording during constant hyperemia was not mandated, we are unable to tell whether a suboptimal post-PCI FFR value is a result of residual diffuse coronary atherosclerosis, imperfect stenting, or pressure drift.
Clinical Implications
The higher the post-PCI FFR value, obtained immediately after DES implantation, the lower the 2-year rate of clinical events related to the stented vessel. However, the present data cannot propose a discrete post-PCI FFR cutoff value that might be used as a surrogate clinical end point or as a target value to optimize PCI results.
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